Heptares Therapeutics
Develops novel, small-molecule drugs for G-protein-coupled receptors.
Launch date
Market cap
-
Enterprise valuation
€364m (Public information from Apr 2017)
Company register number 06267989
Tokyo Japan (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | - | 44.0m | 9.9m | 88.0m | 77.0m |
| % growth | - | - | (78 %) | 789 % | (13 %) |
| EBITDA | 99.0m | (22.0m) | (44.0m) | 33.0m | 22.0m |
| % EBITDA margin | - | (50 %) | (444 %) | 38 % | 29 % |
| Profit | - | 44.0m | 44.0m | - | 33.0m |
| % profit margin | - | 100 % | 444 % | - | 43 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Spinout | |
N/A | Seed | ||
£21.0m | Series A | ||
$21.0m | Series B | ||
$400m Valuation: $400m | Acquisition | ||
$5.5m | Grant | ||
$5.0m | Growth Equity VC | ||
| Total Funding | €53.8m | ||
Related Content
Recent News about Heptares Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Heptares Therapeutics
Edit
ACQUISITION by Heptares Therapeutics Nov 2016
